Microbot Medical Inc.
NASDAQ:MBOTMedical - Instruments & Supplies
-$0.06 today
- Market cap
- $65.73M
- Beta
- 1.04
- P/E (TTM)
- -8.6
- EPS (TTM)
- -$0.21
Volume 0.87M
Average 1.60M
MBOT Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Microbot Medical Inc.NASDAQ: MBOT
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures growth accelerates
Q1 FY2026 capital expenditures of $108K (cash outflow) rose 730.8% year over year, ahead of the +545.8% change in trailing-twelve-month capital expenditures. Sequentially, it rose 332.0% from the prior quarter. Over 3 fiscal years it compounded at -10.6% a year.
Context
- Capital expenditures grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +730.8% holds above the trailing-twelve-month pace of +545.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (60K) USD
- Year-over-year change
- -140.0%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (60K) | -140.0% |
| FY2024 | 2024-12-31 | (25K) | +24.2% |
| FY2023 | 2023-12-31 | (33K) | +60.7% |
| FY2022 | 2022-12-31 | (84K) | -21.7% |
| FY2021 | 2021-12-31 | (69K) | — |
Capital Expenditures vs competitors
How MBOT compares with its peers on the latest reported figures
- Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +545.8% is the 4th highest of 10, against a peer median of +209.0%.
- Capital expenditures amounts to 147.6% of revenue for MBOT, versus a peer median of 29.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $430.32B USD | +6838351.8% | +10.6% | 142623.8% | |
| LTM Mar 2026 | $1.17M USD | +209.0% | +51.4% | — | |
| LTM Mar 2026 | CA$378.49K CAD | +316.9% | -90.4% | 227.9% | |
| LTM Mar 2026 | $212K USD | +102.5% | +49.1% | 0.3% | |
| LTM Mar 2026 | $192.68K USD | +1114.8% | +57.4% | — | |
| LTM Mar 2026 | $155K USD | +545.8% | -10.6% | 147.6% | |
| LTM Mar 2026 | CA$60.26K CAD | +102.4% | -31.1% | — | |
| LTM Mar 2026 | $39K USD | +874.9% | -80.4% | 29.1% | |
| LTM Mar 2026 | $37.26K USD | -9.7% | -60.2% | — | |
| LTM Mar 2026 | $0 USD | +100.0% | — | 0.0% | |
| Peer median (excluding MBOT) | — | +209.0% | -10.2% | 29.1% | |
Competitors are the stored peer set for MBOT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (11.31M) | (13.17M) | (10.74M) | (11.44M) | (13.14M) |
| Depreciation & Amortization | 76K | 102K | 106K | 91K | 47K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.39M | 1.75M | 1.39M | 1.35M | 1.06M |
| Change in Working Capital | 497K | (228K) | (11K) | 942K | (1.01M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | (584K) |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | 497K | (228K) | (11K) | 942K | (424K) |
| Other Non-Cash Items | 1.39M | (7K) | 718K | 234K | 0 |
| Operating Cash Flow | (9.35M) | (11.55M) | (8.53M) | (8.83M) | (13.05M) |
| Capital Expenditures | (69K) | (84K) | (33K) | (25K) | (60K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (3.75M) | (10.06M) | (5.12M) | (82.93M) |
| Sales of Investments | 3.27M | 0 | 12.06M | 6.68M | 10.6M |
| Other Investing Activities | 0 | (3K) | 3K | 0 | 0 |
| Investing Cash Flow | 3.2M | (3.84M) | 1.97M | 1.54M | (72.38M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 4.32M | 6.56M | 7.94M | 86.24M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 0 | 4.32M | 6.56M | 7.94M | 86.24M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (6.15M) | (11.06M) | (2K) | 646K | 810K |
| Free Cash Flow | (9.42M) | (11.63M) | (8.57M) | (8.85M) | (13.11M) |
Microbot Medical Inc.
NASDAQ:MBOT
Intrinsic Alpha fair value
Locked
Current Price
$0.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.